Charles Schwab’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$6.54M Buy
709,616
+39,705
+6% +$366K ﹤0.01% 2216
2025
Q1
$5.75M Sell
669,911
-7,304
-1% -$62.7K ﹤0.01% 2210
2024
Q4
$7.27M Buy
677,215
+11,239
+2% +$121K ﹤0.01% 2156
2024
Q3
$3.78M Buy
665,976
+14,892
+2% +$84.6K ﹤0.01% 2506
2024
Q2
$2.75M Buy
651,084
+21,017
+3% +$88.7K ﹤0.01% 2590
2024
Q1
$3.21M Buy
630,067
+7,757
+1% +$39.5K ﹤0.01% 2456
2023
Q4
$5.79M Buy
622,310
+17,499
+3% +$163K ﹤0.01% 2244
2023
Q3
$3.96M Buy
604,811
+23,549
+4% +$154K ﹤0.01% 2353
2023
Q2
$4.73M Buy
581,262
+21,219
+4% +$173K ﹤0.01% 2253
2023
Q1
$4.8M Sell
560,043
-5,645
-1% -$48.4K ﹤0.01% 2219
2022
Q4
$5.24M Buy
565,688
+22,829
+4% +$211K ﹤0.01% 2194
2022
Q3
$5.6M Buy
542,859
+19,142
+4% +$198K ﹤0.01% 2154
2022
Q2
$5.24M Sell
523,717
-6,969
-1% -$69.8K ﹤0.01% 2168
2022
Q1
$6.53M Buy
530,686
+14,846
+3% +$183K ﹤0.01% 2158
2021
Q4
$8.95M Buy
515,840
+16,634
+3% +$288K ﹤0.01% 2056
2021
Q3
$8.96M Buy
499,206
+340,353
+214% +$6.11M ﹤0.01% 2069
2021
Q2
$3.63M Buy
158,853
+10,214
+7% +$234K ﹤0.01% 2502
2021
Q1
$2.22M Buy
148,639
+14,189
+11% +$212K ﹤0.01% 2629
2020
Q4
$727K Buy
134,450
+8,266
+7% +$44.7K ﹤0.01% 2871
2020
Q3
$575K Hold
126,184
﹤0.01% 2837
2020
Q2
$621K Buy
126,184
+5,647
+5% +$27.8K ﹤0.01% 2754
2020
Q1
$380K Buy
120,537
+14,316
+13% +$45.1K ﹤0.01% 2802
2019
Q4
$276K Hold
106,221
﹤0.01% 2990
2019
Q3
$336K Buy
106,221
+1,042
+1% +$3.3K ﹤0.01% 2941
2019
Q2
$355K Buy
105,179
+89,305
+563% +$301K ﹤0.01% 2961
2019
Q1
$49K Buy
+15,874
New +$49K ﹤0.01% 3130
2018
Q2
Sell
-76,200
Closed -$211K 3115
2018
Q1
$211K Buy
76,200
+25,000
+49% +$69.2K ﹤0.01% 2975
2017
Q4
$165K Hold
51,200
﹤0.01% 3008
2017
Q3
$212K Hold
51,200
﹤0.01% 2993
2017
Q2
$273K Hold
51,200
﹤0.01% 2902
2017
Q1
$294K Hold
51,200
﹤0.01% 2826
2016
Q4
$203K Hold
51,200
﹤0.01% 2961
2016
Q3
$186K Hold
51,200
﹤0.01% 2929
2016
Q2
$313K Buy
+51,200
New +$313K ﹤0.01% 2766